Evidence map›Paper›PMID 40358803›Full record

ArticleJournal of neuro-oncology2025

Outcomes following radiation therapy for embryonal tumor with multilayered rosettes (ETMR): results from the Pediatric Proton/Photon Consortium Registry (PPCR).

Jacquelyn M Krisch, Ralph P Ermoian, Daniel J Indelicato, Jae Y Lee, John P Perentesis, Stephanie M Perkins, Nadia N Laack, John H Chang, Iain J MacEwan, Suzanne L Wolden and 3 more

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01696721 (Proton and Photon Consortium Registry), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01696721 recruitingnot on this map

Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy

TypeobservationalSponsorMassachusetts General HospitalRan2012 to 2028Enrolled5,000ConditionsPediatric Patients Treated With Radiation TherapyArmsNo intervention
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Timing of radiotherapy and autologous stem cell transplantation in embryonal tumor with multilayered rosettes: a critical narrative review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jacquelyn M KrischDepartment of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY, USA.
Ralph P ErmoianDepartment of Radiation Oncology, University of Washington/ Fred Hutchinson Cancer Center, Seattle, WA, USA.
Daniel J IndelicatoDepartment of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
Jae Y LeeProcure Proton Therapy Center, Somerset, NJ, USA.
John P PerentesisDivision of Oncology, Cincinnati Children's Hospital, Cincinnati, OH, USA.
Stephanie M PerkinsDepartment of Radiation Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Nadia N LaackDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
John H ChangOklahoma Proton Center, Oklahoma City, OK, USA.
Iain J MacEwanDepartment of Radiation and Applied Sciences, University of California, San Diego, La Jolla, CA, USA.
Suzanne L WoldenDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dongliang WangDepartment of Public Health and Preventative Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
Torunn I YockDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Paul D AridgidesDepartment of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY, USA. aridgidp@upstate.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEmbryonal tumor with multilayered rosettes (ETMR) is a rare pediatric CNS embryonal tumor with poor survival. The Pediatric Proton/Photon Consortium Registry (PPCR) was queried for outcomes data from prospectively consenting pediatric patients with ETMR treated with proton radiation therapy (RT).

methods20 patients (2013-2021) at 9 institutions had ETMR; 2 with prior RT were excluded from statistical analyses (PPCR ETMR, N = 18). Overall Survival (OS) and Event Free Survival (EFS) analyses were performed using the Kaplan-Meier method and log-rank values. Median follow-up was calculated using the reverse Kaplan-Meier method.

resultsMedian age at RT was 3.0 years (1.7-12.2); median follow-up was 55.5 months (2.6-119.4). 8 patients (44%) expired and 6 patients (33%) are surviving ≥ 55 months. 11 (61%) patients received systemic therapy with stem cell support. The majority (89%) had focal RT (median dose 54 Gy), while 2 patients received craniospinal irradiation (CSI, 30.6-36 Gy). 4-year OS and EFS were 59.6% and 54.2%, respectively. Local control (LC) at 4 years was 81%. No differences in OS or EFS were observed for receipt of systemic therapy with stem cell support (p = 0.361, p = 0.57), progression prior to RT (p = 0.127, p = 0.18), or surgery to RT ≥ 200 days (p = 0.35, p = 0.254). Symptomatic radionecrosis was not reported.

conclusionFocal proton RT provided effective local control as part of multimodality therapy for ETMR, with encouraging survival for this rare and often infant age tumor. Outcomes for CSI were limited to 2 patients treated upfront, and 1 patient receiving salvage CSI for disseminated relapse after focal RT who is surviving > 1 year.

trial registrationDFCI protocol 12-103, clinicaltrials.gov NCT01696721, date of registration 9/27/2012.

Indexed as

Brain NeoplasmsNeoplasms, Germ Cell and EmbryonalProton TherapyChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantMalePrognosisRegistriesSurvival RateTreatment OutcomeCancerETMRPediatricProtonRadiation

Identifiers

PMID40358803

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.